Type 2 diabetic mellitus
Conditions
Interventions
Continue the same oral anti-diabetic drug and the diet/exercise regimen as the preceding 20 weeks for 4 weeks. At week 0, subjects were assigned to either Generic Pioglitazone Hydrochloride 15mg (SAW
Sponsors
Tokyo-Eki Center-building Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetic outpatients over 20 years of age. Treated with 15 mg daily of ACTOS tablets 15 over 20 weeks prior to week -4. Treated with single or double or triple oral hypoglycemic agent including ACTOS tablets 15 over 20 weeks prior to week -4. HbA1c <=7.0% from the data week -4. Written informed consent.
Exclusion criteria
Exclusion criteria: History and/or complication of cardiac failure. Need of insulin therapy. Treated using three or more oral anti-diabetes drugs other than ACTOS tablets 15. Renal or liver dysfunction. Complication with or recent history of myocardial infarction, angina pectoris, cerebral stroke, and cerebral infarction. Malignant neoplasms. Severe ketosis, diabetic coma. History of hypersensitive reaction to pioglitazone. History of major gastrointestinal surgery. Pregnancy. History of alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline in HbA1c at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 12 | — |
Countries
Japan
Contacts
Public ContactYasushi Fukushima
Tokyo-Eki Center-building Clinic Department of Internal Medicine
Outcome results
None listed